A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

Authors

Christos Fountzilas, Roswell Park Comprehensive Cancer Center - Buffalo, NY
Andrew H. Ko, University of California - San Francisco
Erkut Hasan Borazanci, HonorHealth Research Institute - Scottsdale, AZ
James Thomas D'Olimpio, Clinical Research Alliance - Westbury, NY
J Randolph Hecht, UCLA - Santa Monica
Shou-Ching Tang, LSU Health Sciences Center - New OrleansFollow
Anthony F. Shields, Karmanos Cancer Institute - Detroit, MI
Mohamad Adham Salkeni, VCS Research Institute - Fairfax, VA
Glenn Michelson, CG Pharmaceuticals - Orinda, CA
Gene Cho, CG Pharmaceuticals - Orinda, CA
Lorna Liganor, CG Pharmaceuticals - Orinda, CA
Sangsook Ahn Cho, CG Pharmaceuticals - Orinda, CA
Evan Justin Walker, University of California - San Francisco

Document Type

Conference Proceeding

Publication Date

5-29-2024

Publication Title

Journal of Clinical Oncology

Abstract

Annual Meeting of the American Society of Clinical Oncology, 2024; May 21 - June 4, 2024; Chicago, IL

Volume

42

Issue

16

Comments

TPS4206

Recommended Citation

Fountzilas, Christos; Ko, Andrew H.; Borazanci, Erkut Hasan; D'Olimpio, James Thomas; Hecht, J Randolph; Tang, Shou-Ching; Shields, Anthony F.; Salkeni, Mohamad Adham; Michelson, Glenn; Cho, Gene; Liganor, Lorna; Cho, Sangsook Ahn; and Walker, Evan Justin, "A randomized, multi-center, phase 2 study of ivaltinostat (Ival) plus capecitabine (Cape) versus capecitabine alone in the maintenance setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)" (2024). School of Medicine Faculty Publications. 3090.
https://digitalscholar.lsuhsc.edu/som_facpubs/3090
10.1200/JCO.2024.42.16_suppl.TPS4206